全文获取类型
收费全文 | 1779篇 |
免费 | 205篇 |
国内免费 | 38篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 83篇 |
妇产科学 | 49篇 |
基础医学 | 38篇 |
口腔科学 | 13篇 |
临床医学 | 307篇 |
内科学 | 76篇 |
皮肤病学 | 1篇 |
神经病学 | 82篇 |
特种医学 | 25篇 |
外国民族医学 | 1篇 |
外科学 | 447篇 |
综合类 | 282篇 |
预防医学 | 76篇 |
眼科学 | 7篇 |
药学 | 231篇 |
中国医学 | 131篇 |
肿瘤学 | 162篇 |
出版年
2024年 | 11篇 |
2023年 | 35篇 |
2022年 | 66篇 |
2021年 | 89篇 |
2020年 | 95篇 |
2019年 | 70篇 |
2018年 | 81篇 |
2017年 | 90篇 |
2016年 | 83篇 |
2015年 | 62篇 |
2014年 | 107篇 |
2013年 | 142篇 |
2012年 | 97篇 |
2011年 | 101篇 |
2010年 | 71篇 |
2009年 | 72篇 |
2008年 | 73篇 |
2007年 | 87篇 |
2006年 | 64篇 |
2005年 | 61篇 |
2004年 | 59篇 |
2003年 | 46篇 |
2002年 | 47篇 |
2001年 | 41篇 |
2000年 | 38篇 |
1999年 | 36篇 |
1998年 | 32篇 |
1997年 | 20篇 |
1996年 | 24篇 |
1995年 | 22篇 |
1994年 | 18篇 |
1993年 | 13篇 |
1992年 | 11篇 |
1991年 | 7篇 |
1990年 | 10篇 |
1989年 | 7篇 |
1988年 | 4篇 |
1987年 | 5篇 |
1986年 | 5篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1983年 | 1篇 |
1982年 | 5篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1975年 | 1篇 |
1974年 | 2篇 |
排序方式: 共有2022条查询结果,搜索用时 31 毫秒
91.
《Expert opinion on pharmacotherapy》2013,14(18):3217-3235
During the last two decades there have been considerable achievements regarding the management of postoperative nausea and vomiting (PONV). Due to the importance of these symptoms in the aim to streamline clinical processes and to improve patient satisfaction, the debate on the best strategies and also research that focuses on PONV continues. This review summarises the recent developments with respect to the management of PONV. Following a brief review on what is already known on the risk assessment, prevention and treatment of PONV, newer trends in the pharmacological prevention (dexamethasone, neurokinin-1 antagonists, multimodal prevention) will be discussed as well as new insights regarding the value of algorithms for the prevention of PONV. Further, pharmacogenetically based algorithms (according to the metaboliser status) as well as new treatment strategies (dexamethasone, multimodal treatment) will be covered. No drug so far can achieve a reduction of PONV of more than one third. Furthermore, all clinical studies consistently demonstrated that a combination treatment has a simple additive effect without any relevant interaction between different drugs or classes of drugs. The relative reduction of ~ 30% can also be expected from dexamethasone and it is likely that the substances presently in development and in an early clinical use (e.g., neurokinin-1 antagonists) will not represent the new panacea. However, they will probably replenish the existing antiemetic portfolio to better cope with high risk patients. Stratified prevention using pharmacogenetic knowledge is still in the early stages. Algorithms need to be customised to the local settings in order to prove efficient. Treatment remains a most important pillar and there is evidence that the principles of combining antiemetics to prolong effects and improve protection can be similarly applied to treatment. Recent developments in the area of PONV are more related to implementing the already existing evidence than based on the introduction of new molecules. New molecules replenish the pharmacological antiemetic portfolio, which is needed due to the limited efficacy of any single agent available so far. The new neurokinin-1 receptor antagonist, aprepitant, and the long lasting 5-HT3 receptor antagonist palonosetron are the latest developments in this context. Treatment is most important and can also be regarded as a secondary prevention. Due to limited efficacy of single treatment interventions, combination therapy may gain more widespread use in the future. 相似文献
92.
John Chae David McD Taylor Albert G Frauman 《Emergency medicine Australasia : EMA》2011,23(5):554-561
Aim: We aimed to compare the relative efficacy of tropisetron and metoclopramide in treating nausea/vomiting in undifferentiated ED patients. Methods: We undertook a randomized, double‐blinded, clinical trial. Adult patients requiring treatment for nausea/vomiting were randomly assigned to either tropisetron (5 mg) or metoclopramide (10 mg), by i.v. bolus. The primary end‐point was incidence of vomiting. Secondary end‐points were decrease in nausea score from baseline (0–100 VAS), the requirement of ‘rescue’ anti‐emetics, ongoing nausea over 48 h and side‐effects. Results: Fifty patients were enrolled in each group. The demographic variables, presenting complaints and nausea scores at baseline did not differ (P > 0.05). By 180 min, two (4.0%) and nine (18.0%) patients had vomited in the tropisetron and metoclopramide groups respectively (difference 14.0%, 95% CI 0.1–28.0, P= 0.05). Also, there were two and 20 episodes of vomiting respectively. Vomiting rates were 0.02 and 0.16 episodes/person‐hour (difference 0.14 episodes/person‐hour, 95% CI 0.07–0.21, P < 0.001) respectively. By 60 min and thereafter, the decrease in nausea score from baseline was greater (although not significantly so) in the tropisetron group. At 180 min, the decreases were 47.9 mm and 37.0 mm respectively (difference 10.9 mm, 95% CI ?0.7–22.6). Five (10.0%) and 13 (26.0%) patients required a rescue anti‐emetic respectively (difference 16.0%, 95% CI ?0.7–32.7, P= 0.07). Of patients followed up, 13/47 (27.7%) and 20/49 (40.8%) had ongoing nausea respectively (difference 13.2%, 95% CI ?7.7–34.0, P= 0.25). The tropisetron group had less akathisia. Conclusions: Tropisetron was associated with a significantly lower vomiting rate and shows promise as an alternative anti‐emetic in the ED. 相似文献
93.
94.
目的:比较格拉司琼与恩丹西酮防治食管癌术后患者化疗引起恶心、呕吐的作用及毒副反应。方法:回顾性研究439例食管癌术后化疗患者的临床资料,比较格拉司琼和恩丹西酮的治疗效果及毒副反应。结果:吻合VI位于颈部患者比位于胸内患者易发生恶心、呕吐。格拉司琼对化疗后急性(1d)恶心、呕吐有效率为81.6%,延迟性恶心呕吐(2—5d)的有效率分别为75.0%、64.2%、60.8%、56.1%。恩丹西酮对化疗后急性恶心、呕吐有效率为71.4%,延迟性恶心、呕吐的有效率分别为68.7%、57.7%、52.0%、47.1%,两组差异显著(P〈0.05),格拉司琼治疗效果优于恩丹西酮。两者不良反应基本相似。结论:格拉司琼对于防治食管癌术后患者化疗所致恶心、呕吐效果较好。 相似文献
95.
目的评价异丙酚预防妇科腹腔镜手术术后恶心呕吐的效果。本研究通过对70例择期腹腔镜下妇科手术患者的观察,了解其对术后恶心呕吐的预防作用。方法70例ASAI~II级择期腹腔镜下妇科手术患者,随机分为实验组和对照组,实验组在麻醉苏醒后静脉注入异丙酚0.4mg/kg,对照组使用生理盐水2ml。观察麻醉苏醒后24h内两组患者恶心呕吐的发生率。结果实验组在麻醉清醒后24h内恶心呕吐发生率(54.3%)明显低于对照组(74.3%),P<0.05。结论亚催眠量的异丙酚用于预防术后恶心呕吐有一定的疗效。 相似文献
96.
盐酸伊立替康的不良反应及其预防处理 总被引:2,自引:0,他引:2
伊立替康(irinotecan,CPT-11)是喜树碱的半合成衍生物,是选择性拓扑异构酶Ⅰ抑制剂,本品及其体内代谢物SN-38可诱导单链DNA损伤,从而阻断DNA复制,产生细胞毒作用。CPT-11于1998年获FDA批准用于标准化疗方案治疗后转移性结肠直肠癌复发和恶化的二线治疗;于2000年3月获FDA批准联合氟尿嘧啶(5-FU)和亚叶酸钙(CF)用于转移性结肠直肠癌的一线治疗。本品单药有效率在18%左右,联合5-FU和CF的有效率约为50%。CPT-11主要不良反应有迟发性腹泻、恶心、呕吐、中性粒细胞减少症、急性胆碱能综合征等,现就其不良反应的表现类型及预防处理方法进行概述。 相似文献
97.
呕必宁对顺铂所致脑组织5-HT含量变化的影响 总被引:1,自引:1,他引:1
目的:探讨中药复方呕必宁防治化疗药诱发呕吐的中枢机制。方法:应用行为学与分子生物学的方法,比较对照组、NS组、中药组实验动物静脉注射DDP前后,动物呕吐反应,血、脑脊液中DDP浓度,脑脊液、脑组织中的5-HT、5-HIAA含量变化。结果:注射DDP后与NS组比较,中药组猫的呕吐率下降;与此同时脑脊液中DDP浓度明显低于NS组、脑脊液及脑组织中5-HT和5-HIAA浓度较NS组显著降低。结论:呕必宁对DDP所致呕吐反应具有防治作用,其机制可能与降低猫脑脊液中DDP的浓度,降低脑脊液、脑组织中5-HT、5-HIAA含量有关。 相似文献
98.
99.
Seventy-four patients undergoing laparoscopic gynaecological surgery were randomly allocated to two groups receiving cyclizine 50 mg or ondansetron 4 mg at induction of anaesthesia. Anaesthetic and postoperative analgesia regimens were standardised. Approximately half of the patients in each group experienced some degree of postoperative nausea and vomiting (cyclizine, 56%; ondansetron, 54%). There was no difference between groups in respect of pre- and postdischarge incidence. Mean (SD) time to eye opening was significantly prolonged in the cyclizine group [10 (4) min vs. 8 (2) min; p < 0.001], but this had no influence on discharge times. Cyclizine and ondansetron appear equally effective in preventing postoperative nausea and vomiting but the 10-fold price differential favours cyclizine. 相似文献
100.
Whilst conducting a randomised controlled trial into the effects of combination anti-emetics, we endeavoured to confirm that our patient groups were matched using the predictive scoring systems for postoperative nausea and vomiting (PONV) and postoperative vomiting (POV) reported in the literature. One hundred and seventy-seven female patients attending for day case gynaecological surgery were studied and their individual risks of PONV and POV were calculated using four predictive models for PONV and two predictive models for POV. The scoring systems were then evaluated to see if agreement existed between them using the method described by Bland and Altman. Bias and 95% limits of agreement were calculated for each combination. Agreement between scoring systems was poor. As the scoring systems gave widely divergent predictions, we concluded that the predictive risk for PONV or POV would be dependent upon the scoring system chosen, thus limiting their usefulness in this role. 相似文献